Connect with us

Headlines

Visus Therapeutics Raises $20M in Financing

The round was led by new investor LSP.

mm

Published

on

Visus Therapeutics Inc. has closed on $20 million in preferred stock financing.

The financing was led by LSP in Amsterdam, with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation – JJDC, Inc. and other inside investors. In conjunction with the financing, John de Koning, PhD, a general partner at LSP, has joined the company’s board of directors.

The news follows Visus’s March announcement of the close of $36 million in financing.

The company’s lead asset is Brimochol, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia.

Advertisement

Read the latest press release:

SEATTLE — Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today announced the closing of $20 million in preferred stock financing, led by LSP in Amsterdam, along with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation – JJDC, Inc. and other inside investors in the Company. In conjunction with this financing, John de Koning, Ph.D., a General Partner at LSP, has joined the Company’s Board of Directors.

“This financial milestone comes in advance of the Phase 2 topline readout of our lead clinical candidate, BRIMOCHOL™, in development for the treatment of presbyopia,” said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics. “Financing from LSP, one of Europe’s leading investment firms, and Sage Partners expands our base of global investors and will support our drug development and commercial efforts to meet unmet patient needs.”

BRIMOCHOL is an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. It is a proprietary formulation that combines two well-studied, FDA-approved pharmaceuticals: carbachol and brimonidine. BRIMOCHOL has been studied in more than 200 patients across six clinical studies. Topline data from a Phase 2 clinical study evaluating BRIMOCHOL for the treatment of presbyopia are expected in the second half of 2021 and, pending affirmative results, the company plans to immediately initiate pivotal Phase 3 studies.

“I’m particularly excited to welcome John de Koning to our Board and leverage his unparalleled scientific, business and management acumen as we advance BRIMOCHOL into late-stage clinical trials and prepare our commercial strategy,” continued Bergo. “John’s decades of leadership experience advising life science companies will be invaluable as we continue to develop a robust portfolio of novel therapies that promise to set new standards of care in ophthalmology.”

As one of Europe’s leading investors in the healthcare sector, John de Koning brings a wealth of knowledge and industry experience to his role on Visus Therapeutics’ Board of Directors. For more than a decade, he was the organizer of BioCapital Europe, which is regarded as Europe’s premier annual life sciences investment conference.

“After evaluation of several companies in the presbyopia-correcting eye drop category, we are pleased to invest in Visus Therapeutics and help bring what we believe to be a best-in-class treatment in this category to the global markets,” said John de Koning. “I’m looking forward to partnering with my fellow board members and the entire Visus Therapeutics management team to deliver BRIMOCHOL and other exciting ophthalmic therapeutics to patients.”

The company recently announced that it will be hosting its debut Capital Markets Day on August 31 in New York City and virtually for investors and media. More information is available at the Visus 2021 Capital Markets Day registration site.

About Presbyopia

Presbyopia is the loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins when adults are in their 40s and becomes almost universal by age 50.1 Presbyopia impacts billions of people globally with approximately 123 million adults affected in the U.S. alone. 2 Reading glasses are the most common solution for near-vision correction. However, many people often find glasses inconvenient and/or prefer not to wear them for aesthetic reasons. Currently, there are no FDA-approved medications for presbyopia.

About Visus Therapeutics

Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates. For more information, visit: www.visustx.com and follow us on LinkedInTwitter (@VisusTx) and Instagram.

Advertisement

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at [email protected].

SPONSORED VIDEO

Take the VariluxⓇ Challenge

Ready to see what happens when you insist on the best? When Eyecare Professionals insisted on Varilux lenses with every presbyopic patient for 30 days, not only did they provide sharp, seamless vision so that their patients could truly see no limits, but they also created trust, loyalty and increased profitability. See for yourself and take the Varilux Challenge today at VariluxChallenge.com.

#VariluxChallenge #InsistOnVarilux

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular